A prospective randomized controlled study on the adverse reactions caused by uterine contractions after cesarean section under spinal anesthesia treated with remifentanil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500106829

Enrollment

Unknown

Registered

2025-07-30

Start date

2025-09-01

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxytocin adverse reactions

Interventions

Group R:After the fetus is delivered, administer remifentanil TCI at 1.5 ng/ml.

Group B:After the fetus is delivered, administer Butorphanol 1 mg intravenously.

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: cesarean section surgery; age between 18-45 years old; ASA classification I-III; gestational age >= 37 weeks.

Exclusion criteria

Exclusion criteria: Contraindications for spinal anesthesia; anesthesia level higher than T5; concurrent asthma; allergy to butorphanol, Oxy, and RF; severe obstetric complications (such as uncontrolled preeclampsia during pregnancy, uncontrolled gestational diabetes, etc.).

Design outcomes

Primary

Measure	Time frame
The incidence of nausea and vomiting;	—

Secondary

Measure	Time frame
blood pressure;Pronunciation;Oxytocin-related adverse reactions;patient comfort score;Calmness score;	—

Countries

China

Contacts

Public ContactWei Dai

Jianyang People's Hospital

dw963279196@163.com+86 183 8159 6825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026